BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn’s disease. World J Gastroenterol 2017; 23(27): 4958-4967 [PMID: 28785150 DOI: 10.3748/wjg.v23.i27.4958]
URL: https://www.wjgnet.com/1007-9327/full/v23/i27/4958.htm
Number Citing Articles
1
Boris Gole, Uroš Potočnik. Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn’s Disease—A Systematic Review and Gene Ontology AnalysisCells 2019; 8(6): 515 doi: 10.3390/cells8060515
2
Rownaq Fares Al-Sofi, Mie Siewertsen Bergmann, Claus Henrik Nielsen, Vibeke Andersen, Lone Skov, Nikolai Loft. The Association between Genetics and Response to Treatment with Biologics in Patients with Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Inflammatory Bowel Diseases: A Systematic Review and Meta-AnalysisInternational Journal of Molecular Sciences 2024; 25(11): 5793 doi: 10.3390/ijms25115793
3
Michelangelo Rottura, Igor Pirrotta, Domenico Antonio Giorgi, Natasha Irrera, Vincenzo Arcoraci, Federica Mannino, Rosario Campisi, Chiara Bivacqua, Laura Patanè, Giuseppe Costantino, Socrate Pallio, Walter Fries, Anna Viola, Giovanni Pallio. Genetic Polymorphisms on TNFA, TNFRSF1A, and TNFRSF1B Genes Predict the Effectiveness of Anti-TNF-α Treatment in Inflammatory Bowel Disease PatientsBiomedicines 2025; 13(3): 669 doi: 10.3390/biomedicines13030669
4
Giovanni Clemente Actis, Rinaldo Pellicano, Sharmila Fagoonee, Davide Giuseppe Ribaldone. History of Inflammatory Bowel DiseasesJournal of Clinical Medicine 2019; 8(11): 1970 doi: 10.3390/jcm8111970
5
Ziran Wang, Lingjun Kong, Han Zhang, Fengchun Sun, Zijian Guo, Rui Zhang, Yaling Dou. Tumor Necrosis Factor Alpha -308G/A Gene Polymorphisms Combined with Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio Predicts the Efficacy and Safety of Anti-TNF-α Therapy in Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis ArthritisFrontiers in Pharmacology 2022; 12 doi: 10.3389/fphar.2021.811719
6
Duaa Ahmed Elhag, Manoj Kumar, Marwa Saadaoui, Anthony K. Akobeng, Fatma Al-Mudahka, Mamoun Elawad, Souhaila Al Khodor. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic ResponseInternational Journal of Molecular Sciences 2022; 23(13): 6966 doi: 10.3390/ijms23136966
7
Debora Curci, Marianna Lucafò, Adriana Cifù, Martina Fabris, Matteo Bramuzzo, Stefano Martelossi, Raffaella Franca, Giuliana Decorti, Gabriele Stocco. Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel diseaseClinical and Translational Science 2021; 14(6): 2184 doi: 10.1111/cts.13075
8
Khalil Khalaf, Krzysztof Janowicz, Marta Dyszkiewicz-Konwińska, Greg Hutchings, Claudia Dompe, Lisa Moncrieff, Maurycy Jankowski, Marta Machnik, Urszula Oleksiewicz, Ievgeniia Kocherova, Jim Petitte, Paul Mozdziak, Jamil A. Shibli, Dariusz Iżycki, Małgorzata Józkowiak, Hanna Piotrowska-Kempisty, Mariusz T. Skowroński, Paweł Antosik, Bartosz Kempisty. CRISPR/Cas9 in Cancer Immunotherapy: Animal Models and Human Clinical TrialsGenes 2020; 11(8): 921 doi: 10.3390/genes11080921
9
Marjolein Drent, Naomi T. Jessurun, Petal A. Wijnen, Otto Bekers, Aalt Bast. Drug-induced comorbidities in patients with sarcoidosisCurrent Opinion in Pulmonary Medicine 2022; 28(5): 468 doi: 10.1097/MCP.0000000000000889
10
Sükran Erik, EsmaNur Bülbül, Çigdem Sevim, SedaEren Keskin, Mehtap Kara. Risk of Tumor Necrosis Factor Alpha Inhibitors Usage and Related Adverse EffectsThe Journal of Neurobehavioral Sciences 2023; 10(2): 41 doi: 10.4103/jnbs.jnbs_4_23
11
Lili Hu, Handan Tan, Qingfeng Cao, Gangxiang Yuan, Changwei Huang, Guannan Su, Aize Kijlstra, Peizeng Yang. Weak association of a TNFRSF1A polymorphism with Behcet's disease in Chinese HanExperimental Eye Research 2020; 196: 108045 doi: 10.1016/j.exer.2020.108045
12
Marijana Miler, Nora Nikolac Gabaj, Ivana Ćelap, Simeon Grazio, Vedran Tomašić, Alen Bišćanin, Joško Mitrović, Lovorka Đerek, Jadranka Morović-Vergles, Nada Vrkić, Mario Štefanović. Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapyRheumatology International 2021; 41(12): 2195 doi: 10.1007/s00296-021-05016-w
13
Liliana Lykowska-Szuber, Michal Walczak, Agnieszka Dobrowolska, Marzena Skrzypczak-Zielinska. Apoptosis and inflammatory genes variants in primary non-response to anti-TNF therapy in Crohn’s disease patientsEuropean Journal of Gastroenterology & Hepatology 2023; 35(10): 1088 doi: 10.1097/MEG.0000000000002618
14
Maria Markelova, Anastasia Senina, Dilyara Khusnutdinova, Maria Siniagina, Elena Kupriyanova, Gulnaz Shakirova, Alfiya Odintsova, Rustam Abdulkhakov, Irina Kolesnikova, Olga Shagaleeva, Svetlana Lyamina, Sayar Abdulkhakov, Natalia Zakharzhevskaya, Tatiana Grigoryeva. Association between Taxonomic Composition of Gut Microbiota and Host Single Nucleotide Polymorphisms in Crohn’s Disease Patients from RussiaInternational Journal of Molecular Sciences 2023; 24(9): 7998 doi: 10.3390/ijms24097998
15
Mohamed H. Babiker-Mohamed, Sambhawana Bhandari, Prabha Ranganathan. Pharmacogenetics of therapies in rheumatoid arthritis: An updateBest Practice & Research Clinical Rheumatology 2024; 38(4): 101974 doi: 10.1016/j.berh.2024.101974
16
Octavio Ballesta-López, Mayte Gil-Candel, María Centelles-Oria, Juan Eduardo Megías-Vericat, Antonio Solana-Altabella, Hugo Ribes-Artero, Pilar Nos-Mateu, Javier García-Pellicer, José Luis Poveda-Andrés. Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic ReviewInternational Journal of Molecular Sciences 2025; 26(4): 1760 doi: 10.3390/ijms26041760
17
Charalabos Antonatos, Eleana F Stavrou, Evangelos Evangelou, Yiannis Vasilopoulos. Exploring Pharmacogenetic Variants for Predicting Response to Anti-TNF Therapy in Autoimmune Diseases: a Meta-AnalysisPharmacogenomics 2021; 22(7): 435 doi: 10.2217/pgs-2021-0019
18
Marco Gasparetto, Caterina Strisciuglio, Amit Assa, Kostantinos Gerasimidis, Federica Giachero, Jan Novak, Philip Robinson, Bálint Tél, Matthias Zilbauer, Andreas Jenke. Making Research Flourish Through ESPGHANJournal of Pediatric Gastroenterology and Nutrition 2022; 74(2): 301 doi: 10.1097/MPG.0000000000003250
19
Giacomo Cozzi, Laura Scagnellato, Mariagrazia Lorenzin, Edoardo Savarino, Fabiana Zingone, Francesca Ometto, Marta Favero, Andrea Doria, Stephan R. Vavricka, Roberta Ramonda. Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapiesNature Reviews Rheumatology 2023; 19(8): 503 doi: 10.1038/s41584-023-00984-8
20
Hussein Mahajna, Shomron Ben-Horin. Novel bio-genetic predictors of response to biologic treatment in inflammatory bowel diseasesCurrent Opinion in Pharmacology 2020; 55: 132 doi: 10.1016/j.coph.2020.10.011
21
Marianna Lucafò, Raffaella Franca, Davide Selvestrel, Debora Curci, Letizia Pugnetti, Giuliana Decorti, Gabriele Stocco. Pharmacogenetics of treatments for inflammatory bowel diseaseExpert Opinion on Drug Metabolism & Toxicology 2018; 14(12): 1209 doi: 10.1080/17425255.2018.1551876
22
Sophie Vieujean, Edouard Louis. Precision medicine and drug optimization in adult inflammatory bowel disease patientsTherapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231173331
23
Liru Chen, Chuhan Zhang, Ruixuan Niu, Shanshan Xiong, Jinshen He, Yu Wang, Pingxin Zhang, Fengyuan Su, Zishan Liu, Longyuan Zhou, Ren Mao, Shixian Hu, Minhu Chen, Yun Qiu, Rui Feng. Multi‐Omics Biomarkers for Predicting Efficacy of Biologic and Small‐Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic ReviewUnited European Gastroenterology Journal 2024;  doi: 10.1002/ueg2.12720
24
Atsushi Yoshida, Koji Kimura, Toshio Morizane, Fumiaki Ueno. Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational studyEuropean Journal of Gastroenterology & Hepatology 2022;  doi: 10.1097/MEG.0000000000002372
25
Claire Wang, Hannah M. Baer, Daniel R. Gaya, Robert J.B. Nibbs, Simon Milling. Can molecular stratification improve the treatment of inflammatory bowel disease?Pharmacological Research 2019; 148: 104442 doi: 10.1016/j.phrs.2019.104442
26
Raja Atreya, Markus F. Neurath, Britta Siegmund. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?Frontiers in Medicine 2020; 7 doi: 10.3389/fmed.2020.00517
27
Stephen J. O’Brien, Jacob Hallion, Katharina M. Scheurlen, Casey Fiechter, James Burton, Mason Paas, Miranda Schmidt, Sarah Gardner, Maurice R. Eichenberger, Jianmin Pan, Shesh Rai, Susan Galandiuk. Crohn’s disease–related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosisJournal of Gastrointestinal Surgery 2021; 25(9): 2377 doi: 10.1007/s11605-020-04884-0
28
Rita Lauro, Federica Mannino, Natasha Irrera, Francesco Squadrito, Domenica Altavilla, Giovanni Squadrito, Giovanni Pallio, Alessandra Bitto. Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic ReviewBiomedicines 2021; 9(12): 1748 doi: 10.3390/biomedicines9121748
29
Stefania Cheli, Diego Savino, Annalisa De Silvestri, Lorenzo Norsa, Naire Sansotta, Francesca Penagini, Dario Dilillo, Roberto Panceri, Dario Cattaneo, Emilio Clementi, Giovanna Zuin. One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective studyThe Pharmacogenomics Journal 2023; 23(5): 112 doi: 10.1038/s41397-023-00304-z
30
Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin. Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)Česko-slovenská pediatrie 2024; 79(4): 213 doi: 10.55095/CSPediatrie2024/008
31
Mirabella Zhao, Johan Burisch. Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel DiseaseDigestive Diseases and Sciences 2019; 64(7): 1759 doi: 10.1007/s10620-019-05648-w
32
Milena Peruhova, Dimitrina Miteva, Maria Kokudeva, Sonya Banova, Tsvetelina Velikova. Cytokine Signatures in Inflamed Mucosa of IBD Patients: State-of-the-ArtGastroenterology Insights 2024; 15(2): 471 doi: 10.3390/gastroent15020034
33
Javier P Gisbert, María Chaparro. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical PracticeJournal of Crohn's and Colitis 2020; 14(5): 694 doi: 10.1093/ecco-jcc/jjz195
34
Zhen Zeng, Mingshan Jiang, Xi Li, Jing Yuan, Hu Zhang. Precision medicine in inflammatory bowel diseasePrecision Clinical Medicine 2023; 6(4) doi: 10.1093/pcmedi/pbad033
35
Manoj Kumar, Selvasankar Murugesan, Nazira Ibrahim, Mamoun Elawad, Souhaila Al Khodor. Predictive biomarkers for anti-TNF alpha therapy in IBD patientsJournal of Translational Medicine 2024; 22(1) doi: 10.1186/s12967-024-05058-1
36
Toer W. Stevens, Mijntje Matheeuwsen, Maria H. Lönnkvist, Claire E. Parker, Manon E. Wildenberg, Krisztina B. Gecse, Geert R. D’Haens. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease—personalised medicine in its infancyAlimentary Pharmacology & Therapeutics 2018; 48(11-12): 1213 doi: 10.1111/apt.15033
37
Milena Peruhova, Daniela Stoyanova, Dimitrina Georgieva Miteva, Meglena Kitanova, Milko Bozhidarov Mirchev, Tsvetelina Velikova. Genetic factors that predict response and failure of biologic therapy in inflammatory bowel diseaseWorld Journal of Experimental Medicine 2025; 15(1): 97404 doi: 10.5493/wjem.v15.i1.97404